The East African Community Secretariat has urged the Partner States to enhance emergency preparedness and response activities following an outbreak of Ebola in Uganda.

Health authorities in Uganda have declared an outbreak of Ebola after a case of the Sudan ebolavirus
was confirmed in Mubende District in the Central part of the Country.

According to the World Health Organization (WHO), as of 25th September 2022, there were five confirmed deaths and a total of 18 confirmed and 18 probable cases.

Speaking on the outbreak, EAC Council to the Community (CTC) and Acting Deputy Secretary
General for Productive and Social Sectors, Dr. Anthony L. Kafumbe also emphasized the commitment
of the EAC Secretariat to the region.

Dr. Kafumbe added that the Secretariat will work together with Partner States to coordinate emergency preparedness and response activities across the region.

He urged Partner States to “enhance surveillance and laboratory testing especially at border areas; to implement appropriate infection prevention and control measures and increase risk communication and
community awareness of the disease.

“I ask Partner States to consider the deployment of the EAC mobile laboratories to the strategic outbreak hotspots and at the various border Points of Entry. This shall enhance screening of the suspected cases as these Mobile Laboratories have the capabilities to handle such levels 3 and 4 pathogens.”

There have been seven previous outbreaks of the Sudan ebolavirus, with four occurring in Uganda and three in Sudan.

Uganda last reported an outbreak of Sudan ebolavirus in 2012.

In 2019, the country experienced an outbreak of Zaire ebolavirus, crossing from the North-Eastern Region of the neighbouring Democratic Republic of the Congo.

In addition to the trained technical experts, the deployment of the EAC Mobile Laboratories to Kisoro in the Western Region of the Uganda also played an important role in the rapid response in the country.

The WHO has expressed optimism in Uganda’s ability to tackle the epidemic and is helping Ugandan
health authorities with the investigation and deploying Staff to the affected area.

“Uganda is no stranger to effective Ebola control. Thanks to its expertise, action has been taken quickly to detect the virus and we can bank on this knowledge to halt the spread of infections,” said Dr. Matshidiso Moeti, WHO Regional Director for Africa.

Ebola is a severe, often fatal illness affecting humans and other primates.

The virus is transmitted to people from wild animals and spreads in the human population through human-to-human transmission via direct contact (through broken skin or mucous membranes) with blood or body fluids of a person who is sick with or has died from Ebola.

It can be also transmitted through objects that have been contaminated with body fluids like blood, faeces and vomit from a person sick with Ebola or the body of a person who died from Ebola.

The average EVD case fatality rate is around 50 percent. However, case fatality rates have varied from 25 percent to 90 percent in past outbreaks.

Ebola has six different species, three of which (Bundibugyo, Sudan and Zaire) have previously caused large outbreaks.

The incubation period, that is, the time interval from infection with the virus to onset of symptoms, is
from 2 to 21 days.

A person infected with Ebola cannot spread the disease until they develop symptoms.

Symptoms of EVD can be sudden and include fever, fatigue, muscle pain, headache, and sore throat followed by vomiting, diarrhoea, rash and in some cases, both internal and external bleeding.

Early initiation of supportive treatment has been shown to significantly reduce deaths from Ebola –
rehydration with oral or intravenous fluids and treatment of specific symptoms improves survival.

A range of potential treatments including blood products, immune therapies and drug therapies are
currently being evaluated.

While ring vaccination of high-risk people with Ervebo (rVSV-ZEBOV) vaccine has been highly
effective in controlling the spread of Ebola in recent outbreaks in the Democratic Republic of the
Congo and elsewhere, this vaccine has only been approved to protect against the Zaire virus.

Another vaccine produced by Johnson and Johnson may be effective but has yet to be specifically tested
against Ebola Sudan.